Eli Lilly traded at $902.09 this Thursday March 26th, decreasing $14.22 or 1.55 percent since the previous trading session. Looking back, over the last four weeks, Eli Lilly lost 14.25 percent. Over the last 12 months, its price rose by 9.79 percent. Looking ahead, we forecast Eli Lilly to be priced at 888.93 by the end of this quarter and at 811.30 in one year, according to Trading Economics global macro models projections and analysts expectations.
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.